All In Biotech

Drug Trial Radar · NCT02932774

Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)

Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Zyrtec® (Cetirizine HCl) Syrup vs. Claritin® (Loratadine) Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)

Last checked: Nov 20, 2026Latest source record: Apr 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 683 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

683

Actual

Start

Mar 2001

Primary completion

Jul 2001

Study completion Jul 2001

Sponsor

Lead sponsor
Johnson & Johnson Consumer and Personal Products WorldwideJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
Pfizer
First posted
Oct 13, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 6 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this clinical trial was to assess the efficacy and safety of cetirizine HCl syrup vs. loratadine syrup vs. placebo syrup in the treatment of SAR in children 6 to 11 years old.

Conditions

  • Allergic Rhinitis
  • Hay Fever
  • SAR
  • Rhinitis, Allergic, Seasonal

Interventions

  • CetirizineDrug

    Cetirizine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks

  • LoratadineDrug

    Loratadine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks

  • PlaceboOther

    Placebo syrup once daily before 10:00 AM for 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to the Overall endpoint in the subject 24-hour reflective total symptom severity complex (TSSC) scoreTime frame: 2 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.